Countable Labs Secures $26M to Advance Precision Genomics with Countable PCR
June 1, 2026, 9:39 am
Location: United States, Illinois, Chicago
Employees: 11-50
Founded date: 1986
Countable Labs just raised $26 million. This oversubscribed funding round accelerates commercialization of its Countable PCR technology. The platform offers single-molecule quantification, outperforming digital PCR in sensitivity and precision. Funds drive clinical development, global expansion, and new solutions for cell and gene therapy, MRD testing, and molecular diagnostics. ARCH Venture Partners led the investment. Countable PCR aims to democratize advanced genomic testing worldwide, targeting critical rare event detection and genome integrity needs.
Countable Labs, a Palo Alto-based biotechnology firm, announced a significant funding achievement. The company secured $26 million in an oversubscribed financing round. This capital infusion, announced on May 28, 2026, propels the company’s innovative Countable PCR technology. It targets accelerated clinical product development. Global commercialization efforts will also intensify. ARCH Venture Partners spearheaded the investment. F-Prime Capital and Primer Ventures joined the round. This strategic funding positions Countable Labs at the forefront of precision genomics.
Countable PCR represents a leap in molecular diagnostics. It is a single-molecule quantification technology. This platform delivers unparalleled sensitivity. It offers superior precision compared to existing digital PCR methods. The technology eliminates a common hurdle: Poisson correction. It also removes the need for standard curves. This simplifies complex genomic analysis. Labs gain clearer, unambiguous results. Ambiguity, a long-standing challenge in the industry, diminishes significantly.
The Countable PCR system boasts broad dynamic range capabilities. It features powerful multiplexing. This allows for simultaneous analysis of multiple targets. The technology excels at detecting rare genomic events. This high-confidence detection is crucial. It supports advanced research and clinical applications. The platform also enables molecular linkage analysis. It assesses genome integrity with exceptional accuracy. Its advanced 10-color capabilities provide versatility. These features empower diverse scientific and industrial applications.
Countable Labs plans strategic deployment of its new capital. Funds will support fit-for-purpose solutions. These solutions leverage the system's 10-color capabilities. Target applications are critical. Cell and gene therapy manufacturing demands high precision. Minimal residual disease (MRD) testing requires extreme sensitivity. Biomarker validation benefits from robust and accurate tools. Vaccine quality control achieves new standards of excellence. Molecular diagnostics across various indications will also advance. Oncology applications are a key focus for the company. The platform provides superior analytical performance for these vital segments.
The company's vision extends globally. The funding directly supports international commercial expansion. Countable Labs recently appointed Christopher Citraro as Vice President of Global Sales. His leadership will be instrumental. Citraro brings nearly two decades of experience in life sciences sales. He previously held leadership roles at 10x Genomics. His background also includes tenures at Thermo Fisher Scientific, Agena Biosciences, and MP Biomedicals. His expertise will drive the widespread adoption of Countable PCR technology.
The genomics market is dynamic. Traditional PCR technology is ubiquitous. However, it is ripe for disruption. Countable Labs aims to lead this transformation. Their solution offers speed and cost-effectiveness. It provides robust performance. It tackles industry ambiguity head-on. Countable PCR reimagines the PCR process. It delivers an accurate and user-friendly solution. This makes it ideal for distributed use. The company anticipates significant long-term growth.
Countable PCR is set to challenge existing paradigms. It positions itself against digital PCR. It also competes with next-generation sequencing in specific applications. The investment partners recognize this potential. They believe in democratizing access to genomic tools. Their goal is to bring rare event detection capabilities to customers worldwide. Countable PCR's power and robustness are key differentiators. It can serve segments like pathogen tracking. It effectively bridges the gap between complex digital PCR and the discoveries enabled by next-generation sequencing. This allows for clear, unambiguous results at scale.
The future of genomic testing emphasizes simplicity and sensitivity. Cost-effectiveness is also paramount. Countable PCR addresses these demands directly. It represents a significant technological step change. This innovation will broaden access to genomic diagnostics. High-volume genome-based clinical and industrial testing will expand. Countable Labs is poised for success. Its platform supports the development of next-generation therapeutics. It enhances diagnostic accuracy. It accelerates scientific discovery. The company's mission is clear: deliver superior genomics measurement solutions. Countable PCR aims to become an industry benchmark. It will empower researchers and clinicians globally. This funding ensures Countable Labs maintains critical momentum. It provides resources to establish Countable PCR as the new standard for precision measurement.
Countable Labs, a Palo Alto-based biotechnology firm, announced a significant funding achievement. The company secured $26 million in an oversubscribed financing round. This capital infusion, announced on May 28, 2026, propels the company’s innovative Countable PCR technology. It targets accelerated clinical product development. Global commercialization efforts will also intensify. ARCH Venture Partners spearheaded the investment. F-Prime Capital and Primer Ventures joined the round. This strategic funding positions Countable Labs at the forefront of precision genomics.
Countable PCR represents a leap in molecular diagnostics. It is a single-molecule quantification technology. This platform delivers unparalleled sensitivity. It offers superior precision compared to existing digital PCR methods. The technology eliminates a common hurdle: Poisson correction. It also removes the need for standard curves. This simplifies complex genomic analysis. Labs gain clearer, unambiguous results. Ambiguity, a long-standing challenge in the industry, diminishes significantly.
The Countable PCR system boasts broad dynamic range capabilities. It features powerful multiplexing. This allows for simultaneous analysis of multiple targets. The technology excels at detecting rare genomic events. This high-confidence detection is crucial. It supports advanced research and clinical applications. The platform also enables molecular linkage analysis. It assesses genome integrity with exceptional accuracy. Its advanced 10-color capabilities provide versatility. These features empower diverse scientific and industrial applications.
Countable Labs plans strategic deployment of its new capital. Funds will support fit-for-purpose solutions. These solutions leverage the system's 10-color capabilities. Target applications are critical. Cell and gene therapy manufacturing demands high precision. Minimal residual disease (MRD) testing requires extreme sensitivity. Biomarker validation benefits from robust and accurate tools. Vaccine quality control achieves new standards of excellence. Molecular diagnostics across various indications will also advance. Oncology applications are a key focus for the company. The platform provides superior analytical performance for these vital segments.
The company's vision extends globally. The funding directly supports international commercial expansion. Countable Labs recently appointed Christopher Citraro as Vice President of Global Sales. His leadership will be instrumental. Citraro brings nearly two decades of experience in life sciences sales. He previously held leadership roles at 10x Genomics. His background also includes tenures at Thermo Fisher Scientific, Agena Biosciences, and MP Biomedicals. His expertise will drive the widespread adoption of Countable PCR technology.
The genomics market is dynamic. Traditional PCR technology is ubiquitous. However, it is ripe for disruption. Countable Labs aims to lead this transformation. Their solution offers speed and cost-effectiveness. It provides robust performance. It tackles industry ambiguity head-on. Countable PCR reimagines the PCR process. It delivers an accurate and user-friendly solution. This makes it ideal for distributed use. The company anticipates significant long-term growth.
Countable PCR is set to challenge existing paradigms. It positions itself against digital PCR. It also competes with next-generation sequencing in specific applications. The investment partners recognize this potential. They believe in democratizing access to genomic tools. Their goal is to bring rare event detection capabilities to customers worldwide. Countable PCR's power and robustness are key differentiators. It can serve segments like pathogen tracking. It effectively bridges the gap between complex digital PCR and the discoveries enabled by next-generation sequencing. This allows for clear, unambiguous results at scale.
The future of genomic testing emphasizes simplicity and sensitivity. Cost-effectiveness is also paramount. Countable PCR addresses these demands directly. It represents a significant technological step change. This innovation will broaden access to genomic diagnostics. High-volume genome-based clinical and industrial testing will expand. Countable Labs is poised for success. Its platform supports the development of next-generation therapeutics. It enhances diagnostic accuracy. It accelerates scientific discovery. The company's mission is clear: deliver superior genomics measurement solutions. Countable PCR aims to become an industry benchmark. It will empower researchers and clinicians globally. This funding ensures Countable Labs maintains critical momentum. It provides resources to establish Countable PCR as the new standard for precision measurement.